New US patent firms up ground for commercial use of Kyoto's iPS stem cells
This article was originally published in Clinica
Executive Summary
A Japanese university pioneering the development and therapeutic use of induced pluripotent stem (iPS) cells has been granted a new US patent that paves the way for the commercial application and sale of therapies based on the technology.